m6A-centered Crosstalk Information
Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
| Crosstalk ID |
M6ACROT00201
|
[1], [2] | |||
: m6A sites
Direct
Enhancement
RNA modification
NR1I2
NR1I2
ADARB1
Methylation
: modification sites
|
|||||
| m6A Modification: | |||||
|---|---|---|---|---|---|
| m6A Regulator | Methyltransferase-like 3 (METTL3) | WRITER | |||
| m6A Target | Double-stranded RNA-specific editase 1 (ADARB1) | ||||
| Epigenetic Regulation that have Cross-talk with This m6A Modification: | |||||
| Epigenetic Regulation Type | RNA modification (RNAMod) >> Adenosine-to-Inosine editing (A-to-I) | ||||
| Epigenetic Regulator | Double-stranded RNA-specific editase 1 (ADARB1) | WRITER | View Details | ||
| Regulated Target | Nuclear receptor subfamily 1 group I member 2 (NR1I2) | View Details | |||
| Crosstalk Relationship | m6A → A-to-I | Enhancement | |||
| Crosstalk Mechanism | m6A modification directly impacts RNA modification through modulating the expression level of RNA modification regulator | ||||
| Crosstalk Summary | METTL3 methylates Double-stranded RNA-specific editase 1 (ADARB1) mRNA, thereby enhancing its protein expression, which subsequently promotes ADARB1 mediated A-to-I RNA editing of the Nuclear receptor subfamily 1 group I member 2 (NR1I2) transcript. | ||||
| Responsed Drug | Pregnenolone-16alpha-carbonitrile | ||||
| Cell Process | RNA editing | ||||
In-vitro Model |
MGG8 | Glioblastoma | Homo sapiens | CVCL_D1H4 | |
| Hep-G2 | Hepatoblastoma | Homo sapiens | CVCL_0027 | ||
| HepaRG | Hepatitis C infection | Homo sapiens | CVCL_9720 | ||
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
| Nuclear receptor subfamily 1 group I member 2 (NR1I2) | 6 Compound(s) Regulating the Target | Click to Show/Hide the Full List | ||
| pregnenolone-16alpha-carbonitrile | Investigative | [3] | ||
| Synonyms |
16alpha-carbonitrile, pregnenolone
Click to Show/Hide
|
|||
| MOA | Agonist | |||
| External Link | ||||
| trihydroxycholestane | Investigative | [4] | ||
| Synonyms |
5beta-Cholestane-3alpha,7alpha,12alpha-triol; Trihydroxycoprostane; 3,7,12-Trihydroxycholestane; 547-96-6; 5-b-Cholestane-3a ,7a ,12a-triol; (3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,7,12-triol; 3alpha,7alpha,12alpha-Trihydroxycoprostane; 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholestane; 3,7,12-Trihydroxycoprostane; A,5; A)-cholestane-3,7,12-triol; AC1L4NRJ
Click to Show/Hide
|
|||
| MOA | Agonist | |||
| External Link | ||||
| schisandrin A | Investigative | [5] | ||
| Synonyms |
(-)-deoxyschisandrin; (-)-dimethylgomisin J
Click to Show/Hide
|
|||
| MOA | Agonist | |||
| External Link | ||||
| 3-keto-lithocholic acid | Investigative | [6] | ||
| Synonyms |
dehydrolithocholic acid; 3-keto-LCA
Click to Show/Hide
|
|||
| MOA | Agonist | |||
| External Link | ||||
| Hyperforin | Investigative | [7] | ||
| Synonyms |
11079-53-1; hyperforine; hiperforina; UNII-RM741E34FP; CHEBI:5834; RM741E34FP; CHEMBL1237210; (1R,5S,6R,7S)-4-hydroxy-6-methyl-1,3,7-tris(3-methylbut-2-en-1-yl)-6-(4-methylpent-3-en-1-yl)-5-(2-methylpropanoyl)bicyclo[3.3.1]non-3-ene-2,9-dione; (1R,5S,6R,7S)-4-hydroxy-5-isobutyryl-6-methyl-1,3,7-tris(3-methylbut-2-en-1-yl)-6-(4-methylpent-3-en-1-yl)bicyclo[3.3.1]non-3-ene-2,9-dione; HSDB 7646; (+)-Hyperforin; Spectrum5_002025; SCHEMBL98723; CHEMBL501711; GTPL2764; SCHEMBL15557965; Hyperforin, >
Click to Show/Hide
|
|||
| MOA | Binder | |||
| Activity | Ki = 27 nM | |||
| External Link | ||||
| WAY-214950 | Investigative | [8] | ||
| Synonyms |
SCHEMBL1407572; JMC517161 Compound 13; CHEMBL457977; BDBM26067
Click to Show/Hide
|
|||
| MOA | Inhibitor | |||
| Activity | IC50 = 2160 nM | |||
| External Link | ||||
References
: m6A sites
: modification sites